Skip to contentB
Biogen Inc.
B
BIIBBiogen Inc. Q3 2021 · 10-Q
Revenue$2.78B$2.78B−17.7% vs Q3 2020 Net Income$329.20M$329.20M−53.1% vs Q3 2020 EPS Diluted$2.22$2.22−50.2% vs Q3 2020 Operating Income$794,000,000−26.9% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biogen Inc. · CIK 875045 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$763,300,000−30.4% Margins · derivedOperating margin28.6%−3.6 pt vs Q3 2020
Net margin11.8%−8.9 pt vs Q3 2020
ended Sep 30, 2021 · filed Oct 20, 2021 · 20 d after period end